流行性出血热(下称出血热)的治疗迄今尚无特效疗法。近来,由于对其发病机理与病理生理有所认识,特别对免疫功能和出血机制的广泛研究,并积极采取相应的治疗措施,其死亡率有所下降。我们采用PSS配合免疫抑制剂治疗80例获得一定的疗效。特别在发热期应用该疗法后,能提高越期率和明显降低死亡率。现将结果报道如下。临床资料一、一般资料:本组病例为1981年10月～1983年1月住院患者,共计135例(其中55例为对照组)。诊断按1975年全国出血热会议制定的标准。计男性94例,女性41例,最小年龄13岁,最大年龄75岁,中位数33岁。入院时属发热期104例、低血压休克期(下称 The treatment of epidemic hemorrhagic fever (hereinafter referred to as hemorrhagic fever) so far no effective therapy. Recently, due to its understanding of the pathogenesis and pathophysiology, especially for extensive research on immune function and bleeding mechanism, and actively take the appropriate treatment, the mortality rate declined. We use PSS with immunosuppressive agents in 80 patients to obtain a certain effect. Especially in the heat of the application of the therapy, can improve the overdue rate and significantly reduce mortality. The results are reported below. Clinical data First, the general information: This group of patients from October 1981 to January 1983 hospitalized patients, a total of 135 cases (55 cases of control group). Diagnosis by 1975 national hemorrhagic fever meeting set standards. 94 males and 41 females, the youngest 13 years old, the oldest 75 years old, the median 33 years old. Admission is a febrile 104 cases, hypotensive shock (hereinafter referred to